

Join by Web

Join by Text

Go to PollEv.com
Text UNCCN to 22333
Enter UNCCN
Respond to activity

Join by Text

Text UNCCN to 22333
Text in your message

# SITE COORDINATORS / PROMOTERS

Site Coordinators share publicity about upcoming events with other medical professionals so that they can attend at a designated site or via Zoom. They also set up a designated room for each event so that medical professionals can watch a presentation together.

**Promoters** share publicity about upcoming events with other medical professionals so that they can attend at a designated site or via Zoom.

Contact us at unccn@unc.edu to become a site coordinator or promoter!

3

#### FREE CE Credits - CNE (ANCC) - CME - ACPE - ASRT

**Live Lectures** unccn.org Patient Centered Care 2nd Wednesday — 12 pm – 1 pm Research to Practice 4th Wednesday — 12 pm – 1 pm

**Self-Paced, Online Courses** learn.unccn.org

Any day and time that's convenient for you

#### **NO CE Credits Available**

**MediaSite Library** unccn.org/mediasite Any day and time that's convenient for you

**YouTube Channel** unccn.org/youtube Any day and time that's convenient for you

**VuMedi Channel** unccn.org/vumedi Any day and time that's convenient for you

For a complete listing and details on coming events visit: www.unccn.org/events

## 2021 LECTURE SERIES PLANNING

As we say farewell to spring, we recognize that 2021 is not far away.

We ask you to take a few minutes to fill out our nine-question survey, which can be found at:

### www.unc.org/survey

We will use this information to develop what we hope to be the very best Oncology Telehealth lecture lineup ever in 2021.

Please help us by May 29.

5



May 27, 2020


Gastrointestinal Cancer Management in North Carolina: Updates for 2020



Michael S. Lee, MD



## PRESENTE



Michael S. Lee, MD

Dr. Michael Lee is a translational investigator in gastrointestinal cancers, particularly colorectal cancers, focusing on drug development and design of early phase clinical trials of novel therapies.

He is a clinical researcher, designing and writing clinical trials in patients with gastrointestinal cancers and designing correlative studies to determine biomarkers of susceptibility or resistance.

In addition, he is also involved in the preclinical research necessary for drug development and novel pathophysiologic discoveries.

7

Respond at PollEv.com/unccn

☐ Text UNCCN to 22333 once to join, then A, B, C, or D

#### **UNC CANCER NETWORK**

### Which of the following is NOT a form of gastrointestinal cancer?

Stomach A

Pancreatic B

Liver c

Cervix **P** 

Answers to this poll are anonymous

## SCLOSURE

This activity has been planned and implemented under the sole supervision of the course directors, in association with the UNC Office of Continuing Professional Development (UNC CPD). William A Wood, MD, MPH, and CPD staff have no relevant financial relationships with commercial interests as defined by the ACCME.

Michael S. Lee, MD, has no financial relationships with commercial interests as defined by the ACCME. Michael S. Lee, MD, receives speaking fees and research support from Genentech / Roche. The speaker has no other relevant financial relationships with commercial interests as defined by the ACCME.

9



### Gastrointestinal Cancer Management in North Carolina: Updates for 2020

Michael S. Lee, MD
Assistant Professor
Division of Hematology/Oncology, Department of Medicine
University of North Carolina at Chapel Hill
May 27, 2020

11

#### Learning Objectives

- Discuss optimal management for patients with advanced hepatocellular carcinoma with normal liver function
- Discuss new targeted therapy options in subsets of patients with metastatic colorectal cancer
- Discuss optimal duration and course of adjuvant therapy for stage III colon cancer

## Key updates: Focus on targeted and immune checkpoint inhibitor therapies

- Systemic therapy for metastatic gastric and esophageal cancers
- Systemic therapy for unresectable or metastatic hepatocellular carcinoma
- Systemic therapy for metastatic cholangiocarcinoma
- Adjuvant therapy for pancreatic cancer
- Biomarkers in pancreatic cancer
- Adjuvant chemotherapy duration for colon cancer
- · New targeted therapy options for metastatic colorectal cancer

13

#### Case 1

You meet a 60 year old male patient with newly diagnosed cholangiocarcinoma with bone and lung metastases. You decide to send next generation sequencing and additional molecular testing. You also start him on first-line gemcitabine + cisplatin. Unfortunately, he progresses after 6 cycles. He continues to have performance status of 1. Which of the following next line treatment options would not be indicated based on results of the biomarker testing:

- A) Pembrolizumab if MSI-High
- B) Pemigatinib if FGFR2 amplification
- C) Pemigatinib if FGFR2 fusion
- D) FOLFOX if no actionable aberration

You meet a 56 year old female patient who was diagnosed with resectable adenocarcinoma of pancreatic head. She underwent Whipple resection with negative margins and had pT2N0 disease. Which of the following statements about adjuvant therapy is NOT correct?

- A) Adjuvant FOLFIRINOX results in superior overall survival compared to adjuvant gemcitabine
- B) Adjuvant gemcitabine+nab-paclitaxel results in superior disease free survival compared to adjuvant gemcitabine
- C) Adjuvant gemcitabine+capecitabine results in superior overall survival compared to adjuvant gemcitabine

15

#### Case 3

You meet a 49 year old female patient who was diagnosed with metastatic cecal adenocarcinoma with peritoneal carcinomatosis. She received first-line FOLFOXIRI+bevacizumab before eventually progressing. She continues to have performance status of 0. Which of the following next line treatment options would be the best choice based on results of the biomarker testing:

- A) Encorafenib + cetuximab if BRAF V600E mutation
- B) Ipilimumab only if MSI-High
- C) Irinotecan+cetuximab if BRAF V600E mutation
- D) Atezolizumab + cobimetinib only if KRAS mutation

## Systemic therapies for advanced gastroesophageal cancers

Current Therapies (exclusive of immune checkpoint inhibitors)

<u>1L</u>	2L	3L
FOLFOX	Paclitaxel+Ramucirumab*	Irinotecan
(+Trastuzumab if HER2 amp)	Irinotecan-based if neuropathy	Taxane
		Tipiracil+Trifluridine

<sup>\*</sup>Ramucirumab only for adenocarcinoma

17

## Immune checkpoint inhibitors in metastatic gastroesophageal cancers


- 2<sup>nd</sup>-line for esophageal squamous cell carcinoma with PD-L1 CPS ≥10
- 2<sup>nd</sup>-line for any with MSI-High disease
- 3<sup>rd</sup>-line for gastroesophageal adenocarcinoma with PD-L1 CPS ≥1
  - But response rates may be more enriched with CPS ≥10

			PD-L1 CPS ≥10 (n=46)
Response rate	6.4% (2.6-12.8)	15.5% (10.1-22.4)	17.4%

Fuchs CS, et al, JAMA Oncol 2018. Wainberg ZA, et al, GI ASCO 2020

## Pembrolizumab was superior to SOC chemotherapy in esophageal SCC with CPS ≥10: KEYNOTE-181

#### Overall Survival (PD-L1 CPS ≥10)



- Among 168 PD-L1 CPS ≥10 SCC, median OS with pembrolizumab was 10.1 mo (7.0-13.4) vs 6.7 mo (4.8-8.6) with chemo (HR 0.61; 95% CI 0.44-0.85) (Shah MA, et al, ASCO 2019)
- Pembrolizumab was FDA approved in this indication in Jul 2019

19

## Systemic therapies for advanced gastroesophageal cancers

Current Therapies (exclusive of immune checkpoint inhibitors)

<u>1L</u>	2L	3L
FOLFOX	Paclitaxel+Ramucirumab*	Irinotecan
(+Trastuzumab if HER2 amp)	Irinotecan-based if neuropathy	Taxane
	Pembro (SCC w/ CPS≥10; or MSI-H)	Tipiracil+Trifluridine
		Pembro (CPS≥1)

<sup>\*</sup>Ramucirumab only for adenocarcinoma

#### Hepatobiliary cancers

21

## Current landscape of systemic therapies for HCC

First-Line Therapies	Child-Pugh	Median OS	Comparator OS
Atezolizumab + Bevacizumab	Α	Not reached	13.2 mo (sorafenib)
Sorafenib	A or B7	10.7 mo	7.9 mo (placebo)
Lenvatinib	Α	13.6 mo	12.3 mo (sorafenib)
Nivolumab (if not candidate for TKI)		16.4 mo (NS)	14.7 mo (sorafenib)

Second-Line Therapies	Child-Pugh	Median OS	Comparator OS
Regorafenib	Α	10.6 mo	7.8 mo (placebo)
Nivolumab (acc)	A or B	ORR 20%	
Ipilimumab + Nivolumab	Α	ORR 33% (16/49)	
Pembrolizumab	Α	13.9 mo (NS)	10.6 mo (placebo)
Cabozantinib	Α	10.2 mo	8.0 mo (placebo)
Ramucirumab for AFP≥400	Α	8.5 mo	7.3 mo (placebo)

### Atezolizumab + Bevacizumab compared against Sorafenib in unresectable or metastatic HCC


#### **IMbrave150 Study Design** Stratification criteria Key eligibility · Region (Asia, excluding Japana) Atezolizumab 1200 mg IV q3w + bevacizumab 15 mg/kg q3w Locally advanced or metastatic and/or unresectable HCC Until loss ECOG PS (0/1) Macrovascular invasion and/or extrahepatic spread (presence/absence) or un-(Open label) up No prior systemic therapy • Baseline AFP (< 400/≥ 400 ng/mL) (N = 501)Co-primary endpoints Secondary endpoints include • IRF-assessed ORR per RECIST 1.1 and HCC mRECIST Exploratory PRO endpoints TTD° of symptoms (EORTC QLQ-HCC18) Patients (%) with clinically meaningful • IRF-assessed PFS PROs: TTDb of QOL, physical and role functioning (EORTC QLQ-C30) per RECIST 1.1 deterioration in QOL, physical and role

Galle PR, et al, GI ASCO 2020

23


## Atezolizumab + Bevacizumab improved OS and PFS compared to sorafenib

#### IMbrave150 Co-Primary Endpoints: OS and PFS<sup>1</sup>



Galle PR, et al, GI ASCO 2020

## Atezolizumab + Bevacizumab improved OS and PFS compared to sorafenib




Galle PR, et al, GI ASCO 2020

25

## Ipilimumab + Nivolumab recently received accelerated FDA approval

• CheckMate-040

## First-line nivolumab was not superior to sorafenib (CheckMate 459)



	Nivolumab (n=371)	Sorafenib (n=372)	HR
mOS	16.4 mo (13.9-18.4)	14.7 mo (11.9-17.2)	0.85 (0.72-1.02) (p=0.0752)
mPFS	3.7 mo (3.1-3.9)	3.8 mo (3.7-4.5)	


Consider if not a candidate for antiangiogenic therapy and/or TKI, but would not routinely recommend over sorafenib or lenvatinib

Yau T, et al, ESMO 2019

27

## Pembrolizumab trended toward better OS and PFS than best supportive care in 2<sup>nd</sup>-line treatment

 However, based on statistical design of the KEYNOTE-240 study with dual primary endpoints, the result was not deemed statistically significant significant





Finn RS, et al, ASCO 2019

## Current landscape of systemic therapies for HCC

First-Line Therapies	Child-Pugh	Median OS	Comparator OS
Atezolizumab + Bevacizumab	Α	Not reached	13.2 mo (sorafenib)
Sorafenib	A or B7	10.7 mo	7.9 mo (placebo)
Lenvatinib	Α	13.6 mo	12.3 mo (sorafenib)
Nivolumab (if not candidate for TKI)		16.4 mo (NS)	14.7 mo (sorafenib)

Second-Line Therapies	Child-Pugh	Median OS	Comparator OS
Regorafenib	Α	10.6 mo	7.8 mo (placebo)
Nivolumab (acc)	A or B	ORR 20%	
Ipilimumab + Nivolumab	Α	ORR 33% (16/49)	
Pembrolizumab	Α	13.9 mo (NS)	10.6 mo (placebo)
Cabozantinib	Α	10.2 mo	8.0 mo (placebo)
Ramucirumab for AFP≥400	Α	8.5 mo	7.3 mo (placebo)

29

#### Multiple ongoing questions

- Additional novel combinations of immune checkpoint inhibitors and anti-angiogenic (and other) therapies
- Identifying predictive or prognostic biomarkers
- Treatment options for Child Pugh class B patients
- Efficacy of these more effective systemic therapies in earlier stages of disease
- Emphasis on ongoing care for cirrhosis (variceal screening and treatment)

It is an exciting era for novel treatments in hepatocellular carcinoma!

#### Systemic therapies in cholangiocarcinoma


31

## Chemotherapy for metastatic biliary tract and gallbladder cancers


 Gemcitabine/cisplatin is current standard of care and improved OS compared to gemcitabine monotherapy (ABC-02 trial)

	Gem/Cis (n=204)	Gem (n=206)	HR
mOS	11.7 mo	8.1 mo	0.64 (0.52-0.80) (p<0.001)
			Adjusted HR 0.67 (0.54-0.84)
mPFS	8.0 mo	5.0 mo	0.63 (0.51-0.77) (p<0.001)





## FOLFOX superior to best supportive care for 2<sup>nd</sup>-line therapy for metastatic biliary tract cancers (ABC-06)




Lamarca A, et al, ASCO 2019

33

## Emerging biomarkers and targeted therapies in cholangiocarcinomas


Pemigatinib received accelerated FDA approval 4/17/20



Jain A and Javle M. JGO 2016


## FGFR2 inhibitor pemigatinib is effective for cholangiocarcinoma with FGFR2 fusion/rearrangement

- 9% of screened patients had FGFR2 fusion or rearrangement
- ORR 35.5% (26.5-45.4), with 3% complete response. Median duration of response was 9.1 mo



Abou-Alfa GK, et al. Lancet Oncol 2020

35



#### Pemigatinib side effects



(Continued from previous co	lumn)		
Skin exfoliation	5 (3%)	1 (1%)	0
Blood alkaline phosphatase increased	2 (1%)	2 (1%)	0
Acute kidney injury	3 (2%)	1 (1%)	0
Erythema	3 (2%)	1 (1%)	0
Nail disorder	3 (2%)	1 (1%)	0
Aspartate aminotransferase increased	1 (1%)	2 (1%)	0
Alanine aminotransferase increased	2 (1%)	1 (1%)	0
Dysphagia	2 (1%)	1 (1%)	0
Keratitis	2 (1%)	1 (1%)	0
Rash pruritic	1 (1%)	1 (1%)	0
Hyperbilirubinaemia	0	1 (1%)	0
Hypokalaemia	0	1 (1%)	0
Proteinuria	0	1 (1%)	0
Skin toxicity	0	1 (1%)	0
Thrombosis	0	1 (1%)	0
Data include one patient who did was not assigned to any cohort. Fr MedDRA-Medical Dictionary for la adverse events occurring in a 10% 146 patients (no grade 5 adverse ordered relative to the descending events. The following MedDRA p were combined: blood phosphon. † The following MedDRA preferres	GFR= fibroblast Regulatory Active of patients in the events were reported frequency of a preferred terms and terms related	growth factor re vities. Shown are the total study po corted in this study ry grade treatmer related to hypop d hypophosphat to hyperphospha	ceptor. treatment-related pulation of dy). Rows are ent-related advers hosphataemia aemia. utaemia were
combined: blood phosphorus inco	reased; and hyp	erphosphataemi	а.
Table 3: Treatment-related ac			


 Hyperphosphatemia was most common side effect; usually managed with low phosphate diet, and phosphate binders

Abou-Alfa GK, et al. Lancet Oncol 2020

37

## ClarIDHy trial: Ivosidenib in IDH1 mutant improved PFS

- Phase III, 2:1 randomized, double-blind trial of ivosidenib vs placebo in IDH1 mutant advanced cholangiocarcinoma with 1-2 prior treatments
- N=185
- Primary endpoint PFS; crossover was allowed upon progression



Abou-Alfa G, ESMO 2019

#### Pancreatic cancer

- Adjuvant therapy after resection (if no neoadjuvant therapy) depending on patient fitness
  - Modified FOLFIRINOX
  - Gemcitabine + Capecitabine
  - Gemcitabine or 5-fluorouracil/leucovorin




LESS FIT


Adjuvant Chemotherapy	Median OS	Comparator OS
mFOLFIRINOX	54.4 mo	35.0 mo (gemcitabine)
Gemcitabine+Capecitabine	28.0 mo	25.5 mo (gemcitabine)
Adjuvant Chemotherapy	Median Inv Assessed DFS	Comparator DFS

Adjuvant Chemotherapy	Median inv Assessed DFS	Comparator DFS
mFOLFIRINOX	21.6 mo	12.8 mo (gemcitabine)
Gemcitabine+Capecitabine	13.9 mo	13.1 mo (gemcitabine)

39

## Gemcitabine + Nab-paclitaxel DID NOT improve independently assessed DFS (APACT)





 Awaiting mature OS results. However, at this time would not recommend adjuvant gemcitabine + nab-paclitaxel

Tempero MA, et al. ASCO 2019

## Pancreatic cancer: Systemic therapies for metastatic disease


First-line Chemotherapy	Median OS	Comparator OS
FOLFIRINOX	11.1 mo	6.8 mo (gemcitabine)
Gemcitabine+Nab-Paclitaxel	8.5 mo	6.7 mo (gemcitabine)
Gemcitabine+Cisplatin IF BRCA MUTANT	15.5-16.4 mo	

- Actionable biomarkers
  - MSI-High (pembrolizumab)
  - BRCA1/2 germline mutation (olaparib maintenance)

41

BRCA1/2 germline mutations in pancreatic


cancer



Kindler HL, et al, ASCO 2019

- 5.9% in the screening population for POLO trial (Golan T, et al, JCO 2019)
  - 9.5% in U.S.
  - 10.7% in African Americans, vs 6.1% in white, 5.0% in Asian, and 1.6% in other

POLO: maintenance olaparib after disease stability or response after induction platinum-based chemotherapy



Kindler HL, et al, ASCO 2019

43




Table 2. Summary of Adverse Events.☆						
Variable	Olaparib (N=91)		Placebo (N = 60)		Between-Group Difference (95% CI)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3	Any Grade	Grade ≥3
	number (percent)			percentage points		
Adverse event						
Any	87 (96)	36 (40)	56 (93)	14 (23)	2 (-5 to 12)	16 (-0.02 to 31
Fatigue or asthenia	55 (60)	5 (5)	21 (35)	1 (2)	25 (7 to 41)	4 (-4 to 11)
Nausea	41 (45)	0	14 (23)	1 (2)	22 (4 to 36)	-2 (-9 to 3)
Anemia†	25 (27)	10 (11)	10 (17)	2 (3)	11 (-3 to 24)	8 (-2 to 17)
Abdominal pain	26 (29)	2 (2)	15 (25)	1 (2)	4 (-12 to 18)	1 (-8 to 6)
Diarrhea	26 (29)	0	9 (15)	0	14 (-1 to 26)	NC
Decreased appetite	23 (25)	3 (3)	4 (7)	0	19 (5 to 30)	3 (-3 to 9)
Constipation	21 (23)	0	6 (10)	0	13 (-0.02 to 25)	NC
Vomiting	18 (20)	1 (1)	9 (15)	1 (2)	5 (-9 to 17)	-1 (-8 to 5)
Back pain	17 (19)	0	10 (17)	1 (2)	2 (-12 to 14)	-2 (-9 to 3)
Arthralgia	14 (15)	1 (1)	6 (10)	0	5 (-7 to 16)	1 (-5 to 6)
Interruption of intervention owing to adverse event	32 (35)	NA	3 (5)	NA	30 (17 to 42)	NA
Dose reduction owing to adverse event	15 (16)	NA	2 (3)	NA	13 (2 to 23)	NA
Discontinuation of intervention owing to adverse event	5 (5)	NA	1 (2)	NA	4 (-4 to 11)	NA

<sup>\*</sup> The table includes adverse events of any grade that occurred in at least 15% of the patients in the safety population of either trial group during the trial intervention or up to 30 days after discontinuation of the trial intervention. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. NA denotes not applicable, and NC not calculated. The anemia category includes anemia, decreased hemeglobin level, decreased ed-cell count, decreased hematocrit, erythropenia, macrocytic anemia, normochromic anemia, normochromic normocytic anemia, and normocytic anemia.

45


## Pancreatic cancer: Systemic therapies for metastatic disease

First-line Chemotherapy	Median OS	Comparator OS
FOLFIRINOX	11.1 mo	6.8 mo (gemcitabine)
Gemcitabine+Nab-Paclitaxel	8.5 mo	6.7 mo (gemcitabine)
Gemcitabine+Cisplatin IF BRCA MUTANT	15.5-16.4 mo	


- All patients with pancreatic cancer should be screened for BRCA1/2 germline mutations
  - Germline BRCA1/2 mutation is actionable, as olaparib maintenance therapy was FDA approved in Dec 2019
- However we do not know if olaparib maintenance is more effective or more tolerable than maintenance with fluoropyrimidine based chemotherapy

#### Pancreatic cancers: more negative phase III trials

HALO-109-301: 1L Nab-paclitaxel/gemcitabine +/- Pegvorhyaluronidase alfa (PEGPH20)



SEQUOIA: 2L FOLFOX +/- Pegilodecakin



Tempero MA, et al. GI ASCO 2020

Bendell J, et al. GI ASCO 2020

Also CANSTEM111P (gemcitabine+nab-paclitaxel +/- napabucasin), RESOLVE (gemcitabine+nab-paclitaxel +/- ibrutinib), and others


Novel approaches and enrollment in clinical trials are critical to move the needle in this devastating disease

47

### Adjuvant therapy duration in stage III colon cancer

- MOSAIC had established 6 mo duration of adjuvant fluoropyrimidine
   + oxaliplatin to be the standard duration of treatment
- Cumulative neurotoxicity becomes more prominent with longer duration of therapy
- The IDEA study was a preplanned, pooled analysis of 6 randomized phase III trials occurring concurrently internationally to evaluate if 3mo of either FOLFOX or CAPOX was noninferior to 6 mo, with primary endpoint of 3-yr DFS.
- In overall analysis, noninferiority of 3 mo could not be concluded. HR 1.07 (1.00-1.15). However, further subgroup analyses were done

## Important to consider by risk group and chemo regimen



I recommend 3 mo of CAPOX for the low risk T1-3 N1 patients

For high risk T4 or N2 patients 6 mo of therapy has best evidence, but if giving CAPOX could consider 3 mo of therapy

I give recommendations but this does require shared decision-making.

Shi Q, et al, ASCO 2017


49

## Updates in targeted therapy in metastatic colorectal cancer

- BRAF V600 mutations are actionable with combination targeted therapies
- MSI-High is critical to identify given susceptibility to immune checkpoint inhibitors

#### BRAF mutations confer poor prognosis


- Found in ~10% of patients with colorectal cancer
- Single-agent BRAF inhibitors were insufficient to yield responses, primarily due to feedback activation of EGFR
- · Combination therapies are thus needed



Kopetz S, et al, GI ASCO 2020


51

## Combination therapies significantly improved overall survival compared to control



Kopetz S, et al, GI ASCO 2020

## Updated survival analysis shows encorafenib+cetuximab doublet improves OS



Kopetz S, et al, GI ASCO 2020

53

## Microsatellite instability is predictive for response to immune checkpoint inhibitors

Immune Checkpoint Inhibitor	N	ORR	Median OS
Pembrolizumab 2L (KEYNOTE-164)	63	33% (22-46%)	NR (19.2-NR)
Pembrolizumab 3L (KEYNOTE-164)	61	33% (21-46%)	31.4 mo (21.4-NR)
Nivolumab (CheckMate-142)	74	31.1% (20.8-42.9)	NR (18.0-NR)
Ipilimumab + Nivolumab (Checkmate-142)	119	55% (45.2-63.8)	NR

Le DT, et al, J Clin Oncol 2019; Overman MJ, et al, Lancet Oncol 2017; Overman MJ, et al, J Clin Oncol 2018

- Data for use in earlier lines of therapy emerging
  - Pembrolizumab was announced in Apr 2020 to result in superior PFS compared to SOC FOLFOX or FOLFIRI based chemotherapy regimen in KEYNOTE-177. Final OS results pending
  - 1L Ipilimumabnivolumab had 60% response rate (Lenz HJ, et al, GI ASCO 2020)

You meet a 60 year old male patient with newly diagnosed cholangiocarcinoma with bone and lung metastases. You decide to send next generation sequencing and additional molecular testing. You also start him on first-line gemcitabine + cisplatin. Unfortunately, he progresses after 6 cycles. He continues to have performance status of 1.

55

#### Case 1

Which of the following next line treatment options would not be indicated based on results of the biomarker testing:

- A) Pembrolizumab if MSI-High
- B) Pemigatinib if FGFR2 amplification
- C) Pemigatinib if FGFR2 fusion
- D) FOLFOX if no actionable aberration

You meet a 56 year old female patient who was diagnosed with resectable adenocarcinoma of pancreatic head. She underwent Whipple resection with negative margins and had pT2N0 disease.

57

#### Case 2

Which of the following statements about adjuvant therapy is NOT correct?

- A) Adjuvant FOLFIRINOX results in superior overall survival compared to adjuvant gemcitabine
- B) Adjuvant gemcitabine+nab-paclitaxel results in superior disease free survival compared to adjuvant gemcitabine
- C) Adjuvant gemcitabine+capecitabine results in superior overall survival compared to adjuvant gemcitabine

You meet a 49 year old female patient who was diagnosed with metastatic cecal adenocarcinoma with peritoneal carcinomatosis. She received first-line FOLFOXIRI+bevacizumab before eventually progressing. She continues to have performance status of 0.

59

#### Case 3

Which of the following next line treatment options would be the best choice based on results of the biomarker testing:

- A) Encorafenib + cetuximab if BRAF V600E mutation
- B) Ipilimumab only if MSI-High
- C) Irinotecan + cetuximab if BRAF V600E mutation
- D) Atezolizumab + cobimetinib only if KRAS mutation

#### References


- Abou-Alfa G, "Claridhy: A Global, Phase 3, Randomized, Double-Blind Study of Ivosidenib (IVO) Vs Placebo in Patients with Advanced Cholangiocarcinoma (CC) with an Isocitrate Dehydrogenase 1 (IDH1) Mutation." ESMO 2019. https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/ClarIDHy-A-global-phase-3-randomized-double-blind-study-of-ivosidenib-IVO-vs-placebo-in-patients-with-advanced-cholangiocarcinoma-CC-with-an-isocitrate-dehydrogenase-1-IDH1-mutation
- Abou-Alfa GK, et al. "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study." <u>Lancet Oncol.</u> 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
- Finn RS, et al, "Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC)." Journal of Clinical Oncology 37, no. 15\_suppl (May 20, 2019) 4004-4004. DOI: 10.1200/JCO.2019.37.15 suppl.4004
- Fuchs CS, et al. "Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. Phase 2 Clinical KEYNOTE-059 Trial." JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013
- Galle PR, et al. "2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC." GI ASCO 2020. https://www.ascopost.com/news/january-2020/patient-reported-outcomes-from-imbrave150-beacon-crc/
- Golan T, et al. "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer." N Engl J Med 2019; 381:317-327. DOI: 10.1056/NEJMoa1903387
- Jain A and Javle M. "Molecular profiling of biliary tract cancer: a target rich disease." JGO 2016m vol 7, no 5. doi: 10.21037/jgo.2016.09.01
- Kindler HL, et al. "Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a
  germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial." Journal of Clinical Oncology 37, no. 18\_suppl. DOI:
  10.1200/JCO.2019.37.18\_suppl.LBA4

61

#### References

- Kopetz S, et al. "2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC." GI ASCO 2020. https://www.ascopost.com/news/january-2020/patient-reported-outcomes-from-imbrave150-beacon-crc/
- Lamarca A, et al. "ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy." Journal of Clinical Oncology 37, no. 15\_suppl (May 20, 2019) 4003-4003. DOI: 10.1200/JCO.2019.37.15\_suppl.4003
- Shi Q, et al. "Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration." Journal of Clinical Oncology 35, no. 18\_suppl. DOI: 10.1200/JCO.2017.35.18\_suppl.LBA1
- Tempero MA, et al. "APACT Trial: Nab-paclitaxel/Gemcitabine vs Gemcitabine Alone in Adjuvant Treatment of Pancreatic Cancer." ASCO 2019. https://www.ascopost.com/issues/july-10-2019/apact-trial/
- Valle J, et al. "Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer," N Engl J Med 2010; 362:1273-1281. DOI: 10.1056/NEJMoa0908721
- Wainberg ZA, et al. "Survival Benefits Achieved with Pembrolizumab in MSI-H and CPS ≥ 10 Gastric/Gastroesophageal Junction Cancer." GI ASCO 2020. https://www.ascopost.com/issues/march-25-2020/survival-benefits-achieved-with-pembrolizumab-in-some-gastric-and-gastroesophageal-junction-cancers/
- Yau T, et al. "Clinical Benefit with First-Line Immunotherapy in Advanced Hepatocellular Carcinoma [Esmo 2019 Press Release]," ESMO 2019. https://www.esmo.org/newsroom/press-office/esmo-congress-hepatocellular-carcinoma-cancer-checkmate459-yau





# THANK YOU FOR PARTICIPATING!

#### **UNC CANCER NETWORK**

Email: unccn@unc.edu Call: 919-445-1000

Send us an email to sign up for our monthly e-newsletter.

Check us out at unccn.org





65

## 2021 LECTURE SERIES PLANNING

As we say farewell to spring, we recognize that 2021 is not far away.

We ask you to take a few minutes to fill out our nine-question survey, which can be found at:

www.unc.org/survey

We will use this information to develop what we hope to be the very best Oncology Telehealth lecture lineup ever in 2021.

Please help us by May 29.

## PCOMING LIVE LECTURES



Live

June 10 12:00 PM The Role of Race in Cancer Diagnosis, Treatment, and Survivorship Samuel Cykert, MD Christina Yongue, MPH, MCHES



Live Lecture

June 26 12:00 PM Radiation Oncology in North Carolina: Updates for 2020 Trevor Royce, MD, MPH

For a complete listing and details on coming events visit: www.unccn.org/events

67

# SELF-PACED, ONLINE COURSES



Meeting the Needs of Undocumented Patients with Cancer Julia Rodriguez-O'Donnell, LCSW, OSW-C



Immune (check point) Related Adverse Events Frances Collichio, MD

Today's lecture will be available in *July 2020* as a *FREE*, Self-Paced, Online Course

For a complete listing and details on coming events visit: www.unccn.org/events